Wall Street Breakfast Google spinoff sees AI drug trials this year
Jan 21, 2025
Isomorphic Labs is gearing up for groundbreaking clinical trials of AI-designed drugs, expected to reshape the pharmaceutical landscape. Meanwhile, a major $300 million remodel is set to revive MGM Grand Vegas, targeting luxury clientele. There's also a buzz about Bank of America's top stock picks for the coming years, as they delve into market trends and consumer insights. Tune in for a mix of innovation and market predictions!
AI Snips
Chapters
Transcript
Episode notes
AI Drug Discovery
- Isomorphic Labs, a Google spinoff, aims to use AI to accelerate drug discovery, potentially shortening the process from years to weeks or months.
- They plan to start clinical trials of AI-designed drugs by the end of 2025.
2025 Market Outlook
- Big cap tech, financials, and certain healthcare areas with AI exposure are expected to perform well in 2025.
- Sticking with these successful sectors is recommended.
Apple Downgrade
- Jeffries downgraded Apple due to weak iPhone sales and the general consumer electronics market downturn, lowering their price target.
- Slower AI uptake and potential delays in Apple's advanced packaging roadmap contributed to the downgrade.